FGFR3 and neoplasm: However, in bladder cancer, APOBEC-low expressing tumours often present mutations in FGFR3 and RAS family of oncogenes; whereas APOBEC-high expressing tumours usually have mutations in DNA damage response genes and chromatin regulatory genes, an enhanced immune response and better overall survival [184].